Cell and gene therapy

Cryoport & CGT Catapult facility
#Cell and gene therapy #CGT Catapult #Cryoport #Partnership #Supply chain #UK

New CGT supply chain logistics centre for Stevenage, UK, bio hub

Cryoport and the Cell and Gene Therapy Catapult have entered into a new strategic partnership to support the advancement of cell and gene therapies. As part of the deal, Cryoport will establish a Good Manufacturing Practice (GMP)-compliant global supply chain logistics centre in the UK at… Read More

#News

#Automation #Cell and gene therapy #CTMC #MD Anderson Cancer Center #National Resilience #ScaleReady

CGT partnership to automate for greater patient accessibility 

ScaleReady and CTMC, a joint venture between National Resilience and MD Anderson Cancer Center, have partnered to help lessen the manufacturing barriers holding back life-saving cell and gene therapies (CGTs) from reaching more patients by integrating automation tools.   The agreement will enable CTMC to strategically scale the recently completed… Read More

#Business & Investment #News

#BioIVT #Cell and gene therapy #Cell therapy #GMP #Manufacturing #Regulatory #Webinar

Webinar: Avoid unnecessary delays getting cell therapies to market

Both GTPs and GMPs must be followed to get cell-based advanced therapies or tissue-based therapy products to market. Learn about important considerations when sourcing Leukocytes/Cellular starting materials and related ancillary products that must be factored into your programme to efficiently move through the clinical pipeline and successfully receive regulatory approval. Read More

#News

CRISPR gene editing
#Aldevron #Cell and gene therapy #CRISPR #Gene editing #Integrated DNA Technologies #Partnership

Partners working to realise the future of genomic medicine

CRISPR gene editing companies Integrated DNA Technologies (IDT) and Aldevron have inked a new global distribution agreement to expand CRISPR products for cell and gene therapy customers. IDT will stock and sell three additional research use only (RUO) and current good manufacturing practice (cGMP) CRISPR nucleases… Read More

#News

Cell and gene therapies
#Advanced Therapies #Advanced Therapies Europe #Cell and gene therapy #Cell therapy #Gene therapy

Advanced Therapies Europe: From bench to bedside and boardroom

Advanced Therapies Europe took place from 9-12 September 2023 in Portugal. DDW’s Megan Thomas asked attendees: What is most important to scale from discovery to commercialisation of cell and gene therapies (CGTs)? Joel Eichmann, Co-Founder, Green Elephant Biotech It always comes down to time-to-market and risk minimisation. To cover these,… Read More

#Exclusive Content

Cell and gene therapy
#CDMO #Cell and gene therapy #eBook #Gene therapy #Manufacturing

eBook: Analytical methods for viral vector development in gene therapy

The eleventh eBook of the Hamilton series ‘Analytical Methods for Viral Vector Development and Manufacturing in Gene Therapy’ is now available. Download the eBook to learn about: Gene therapy: history, viral vectors and the role of CDMOs Automation of analytical assays during viral vector development and manufacturing… Read More

#News

#CDMO #Cell and gene therapy #Gene therapy #Manufacturing

Analytical methods for viral vector development and manufacturing in gene therapy

In the eleventh eBook of the Hamilton series ‘Analytical Methods for Viral Vector Development and Manufacturing in Gene Therapy’, we learn about: Gene therapy: history, viral vectors and the role of CDMOs Automation of analytical assays during viral vector development and manufacturing The solutions that Hamilton offers to customers working… Read More

#Resources

#Biotech #Cell and gene therapy #Clinical trials #Market reporting #Oncology

New podcast: A deep dive into US drug discovery

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “US biotech: Focus on positive growth… Read More

#News

#Biologics #CAR-T #Cell and gene therapy #Cell therapy #PCR #Whitepaper

Whitepaper on digital PCR for lentiviral vector characterisation

A new Whitepaper is available from Thermo Fisher Scientific, entitled ‘Lentiviral vector characterization for cell and gene therapy manufacturing using the QuantStudio Absolute Q Digital PCR System’. Recombinant lentiviral vectors are used for ex vivo transgene delivery in several gene-modified cell therapies, such as chimeric antigen receptor (CAR) T cell therapy. Read More

#News

#Biologics #CAR-T #Cell and gene therapy #Cell therapy #PCR

Explore the power of digital PCR for lentiviral vector characterisation

Recombinant lentiviral vectors are used for ex vivo transgene delivery in several gene-modified cell therapies, such as chimeric antigen receptor (CAR) T cell therapy. Reliable analytical methods such as digital PCR to characterise lentiviral vectors and the cells transduced with them are critical to helping ensure the safety and efficacy of… Read More

#Resources

#Cancer research #CAR-T #Cell and gene therapy #Collaboration #Oncology #Solid tumours

New DDW Highlights podcast now live

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news headlines this week reflect the level of interest in cell & gene… Read More

#News

EU and US flags
#Advanced Therapies #Cell and gene therapy #EMA #FDA #Regulatory

Overcoming diverging regulatory expectations to bring CGTs to market

Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at AmerisourceBergen, and Cori Gorman, Senior Director of CMC and Regulatory Affairs at Biopharma Excellence, offer advice on navigating the different and sometimes contradictory regulatory requirements in the US and EU. Over the past few decades, the… Read More

#Exclusive Content #Regulatory #Trends & Analysis

#Cancer research #CAR-T #Cell and gene therapy #Collaboration #Oncology #Solid tumours

This week in drug discovery (7-11 August)  

News round-up for by DDW Digital Content Editor Diana Spencer. The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients. Traditionally successful… Read More

#News

Advanced therapies
#Advanced Therapies #CAR-T #Cell and gene therapy #Drug development

Commercialising advanced therapies: Industry perspectives 

Dr Christian K Schneider, Head of Biopharma Excellence at PharmaLex, presents the findings of an industry panel debate on barriers to commercialisation of novel treatments, and the most effective strategies to bring them to market.  With so many exciting novel treatments emerging from the labs, biotechs and pharma companies need… Read More

#Exclusive Content #Opinion

Human eye
#Cell and gene therapy #Gene therapy #Krystal Biotech #Ophthalmology

First-of-its-kind gene therapy restores vision in DEB patient

A dystrophic epidermolysis bullosa (DEB) patient at the Bascom Palmer Eye Institute, University of Miami, US, has regained his vision after being the first person to receive a formulation of gene therapy Vyjuvek suitable for the eyes. DEB is a rare genetic condition that makes the… Read More

#News #Trending News

#Acquisition #Biopharma #Biotechnology #CDMO #Cell and gene therapy #Cold chain #Drug development #GSK #Pfizer #Regulatory #Supply chain

New podcast: A business case for drug discovery

This is the latest episode of the free DDW narrated podcast, “A business case for drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “A deal in the making”, “Why project management… Read More

#News